") announced today the submission of a Phase III protocol to the U.S. Food and Drug Administration for a randomized, double-blind study in metastatic melanoma.
http://technews.tmcnet.com/news/2013/07/26/7305509.htm
http://technews.tmcnet.com/news/2013/07/26/7305509.htm
No comments:
Post a Comment